Non-Invasive Chromosomal Evaluation of 22q11.2 (22Q)

Cindy Cisneros

Status: Completed

Conditions: 22q.11.2 Deletion/Duplication

Study type: Observational

Funder types: Industry

Identifiers

NCT02541058

AD202

Details and patient eligibility

About

This study is being conducted to develop and evaluate a cell-free fetal DNA test (Harmony) for non-invasive prenatal detection of 22q11.2 chromosomal deletion or duplication.

Enrollment: 420 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Patient is ≥18 years of age and able to provide consent or, if under the age of 18, the patient has parental consent and child assent provided as required by the governing ethics committee.

2. If pregnant, patients must have a singleton pregnancy and be at least 10 weeks gestation at the time of the study blood draw.

3. Patients must meet at least one of the following conditions at the time of enrollment:

   1. are pregnant with abnormal fetal cardiac findings on ultrasound and is undergoing evaluation with prenatal genetic testing or planned post-natal genetic testing in the immediate newborn period;
   2. are pregnant with fetal ultrasound findings consistent with a 22q11.2 deletion/duplication phenotype and is undergoing evaluation with prenatal genetic testing or planned post-natal genetic testing in the immediate newborn period;
   3. are pregnant with a fetus known to have a 22q11.2 deletion/duplication confirmed by genetic testing with documentation is available;
   4. are biologically related parent of an enrolled child has chromosomal deletion/duplication in the region of 22q11.2;

4. If the site is selected to enroll control patients, they must be pregnant women undergoing prenatal genetic evaluation for 22q11.2 deletion/duplication.

Exclusion Criteria

Patients meeting any of the following criteria will be excluded from the study:

1. Patient has history of malignancy treated with chemotherapy and/or major surgery, or bone marrow transplant.

Trial design

420 participants in 2 patient groups

Confirmed 22q.11.2 deletion/duplication

Suspected 22q.11.2 deletion/duplication